Categories
Archives
Receive Email Updates
-
-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me
Warren D. Woessner Pages
Archives
Tag Archives: ip
USPTO Publishes Final Rules for Micro-Entity Status and Fee Schedule
On December 19, 2012, the Patent Office published the final rule: “Changes to Implement Micro Entity Status for Paying Patents Fees” –77 Fed. Reg. 75019–and on January 18, 2013 the final fee schedule is expected to be published (link below). … Continue reading
Supreme Court Denies Cert. in Sherley v. Sebelius
The pesky worry about a possible Supreme Court review of the ruling by the D.C. Court of Appeals affirming the Circuit Court’s dismissal of a challenge to the 2009 NIH Stem Cell Funding Guidelines – which permitted NIH funding of … Continue reading
Cold Spring Harbor Laboratory Conference on Patenting in the Life Sciences
I will be speaking at this conference in March, 2013. ************************* GENES & DIAGNOSTICS: A MYRIAD OF ISSUES IN BIOTECH IP March 10 – 13, 2013 REGISTRATION DEADLINE: March 1st http://meetings.cshl.edu/meetings/2013/patent13.shtml Cold Spring Harbor Laboratory is pleased to announce a … Continue reading
Posted in Conferences and Classes
Tagged biotechnology, biotechnology law, intellectual property, ip, Patent Law, Warren Woessner
1 Comment
In re Rosuvastatin Calcium Patent Litigation – Making “Therasense” out of Confusion
Recently, a divided three judge panel sorting out a multi-party Hatch-Waxman suit, ruled that the patentee, Shinonogi, had not committed inequitable conduct in obtaining the patent that was subsequently reissued so as to obtain narrow claims focused on Rosuvastatin, or … Continue reading
Posted in Inequitable Conduct/Rule 56, Reissue
Tagged AstraZenca, biotechnology, biotechnology law, biotechnology news, Crestor, Federal Circuit, Hatch-Waxman, inequitable conduct, intellectual property, ip, Patent Law, patents, reissue, Rosuvastatin, Shinonogi, Therasense, Warren Woessner
1 Comment